SCHEMBL3513571

SCHEMBL3513571

COCc1ccc(-c2ccc3ncc4c(c3c2)n(-c2cn(C)nc2Cl)c(=O)n4C)cn1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATM Q13315 14/20 0.64
ATR Q13535 5/20 0.64
MTOR P42345 8/20 0.55
PRKDC P78527 1/20 0.55
PIK3CD O00329 4/20 0.47
PIK3CA P42336 4/20 0.47
PIK3CB P42338 4/20 0.47
PIK3CG P48736 4/20 0.47
KCNH2 Q12809 5/20 0.46
CSNK2A2 P19784 1/20 0.42
FECH P22830 1/20 0.42
CLK1 P49759 1/20 0.42
GSK3A P49840 1/20 0.42
DYRK1A Q13627 1/20 0.42
MELK Q14680 1/20 0.42
MYLK3 Q32MK0 1/20 0.42
PIK3C3 Q8NEB9 1/20 0.42
PIP4K2C Q8TBX8 1/20 0.42
TP53RK Q96S44 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3515401 0.90 ATM (0.49) ATMATRMTORPRKDCPIK3CD
SCHEMBL3516570 0.88 ATM (0.49) ATMATRMTORPRKDCPIK3CD
SCHEMBL3513401 0.87 ATM (0.47) ATMATRMTORPRKDCPIK3CD
SCHEMBL3515526 0.87 MTOR (0.47) ATMATRMTORPRKDCPIK3CD
SCHEMBL3516548 0.86 PIK3CD (0.47) ATMATRMTORPRKDCPIK3CD
SCHEMBL3518255 0.86 MTOR (0.52) ATMATRMTORPRKDCPIK3CD
SCHEMBL3515005 0.86 MTOR (0.52) ATMATRMTORPRKDCPIK3CD
SCHEMBL3518296 0.85 ATM (0.46) ATMATRMTORPRKDCPIK3CD
SCHEMBL2068795 0.85 ATM (0.46) ATMATRMTORPRKDCPIK3CD
SCHEMBL3516255 0.85 ATM (0.51) ATMATRMTORPRKDCPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 US claimed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US claimed
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 ATM 995/4885ATR 2741/4885MTOR 374/4885
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 ATM 995/4885ATR 2741/4885MTOR 374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.